Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on the use of ibrutinib as frontline therapy in chronic lymphocytic leukemia (CLL), highlighting the long-term follow-up results of the ECOG-E1912 (NCT02048813) study evaluating this first-in-class BTK inhibitor plus rituximab. Whilst a large body of evidence has shown that ibrutinib is well tolerated in young patients, it has been reported that older patients experience higher toxicity and have poorer outcomes. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.